Reported Earlier: Kura Oncology And Kyowa Kirin To Present Eight Ziftomenib Abstracts At ASH 2026, Highlighting Promising AML Combination Data And Expanded Clinical Potential

– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –

– Longer-term Phase 1b data for ziftomenib plus venetoclax and azacitidine in frontline AML support the ongoing Phase 3 KOMET-017 registrational study –

– Exploratory analysis to evaluate ziftomenib clinical activity beyond NPM1-mutated and KMT2A-rearranged subtypes –

– A total of four oral presentations and four posters to highlight the expanding potential of menin inhibition with ziftomenib across AML treatment settings and combinations –

– Investor webcast on December 15, 2026, at 8:30 a.m. ET / 5:30 a.m. PT –

SAN DIEGO and TOKYO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Co., Ltd (TSE: 4151) today announced that eight abstracts related to ziftomenib, including four oral presentations and four posters, have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, taking place December 12-15 in New Orleans. Kura and Kyowa Kirin are working together under a strategic collaboration and license agreement to develop and commercialize ziftomenib for the treatment of acute myeloid leukemia (AML) worldwide.

The presentations will include the first clinical results for ziftomenib in combination with the FLT3 inhibitors quizartinib and gilteritinib, longer-term frontline data for ziftomenib plus venetoclax and azacitidine, and an exploratory analysis of ziftomenib activity in molecularly defined AML subtypes beyond NPM1-mutated and KMT2A-rearranged disease.